Business Context and Reporting Period
Company: NeuroSense Therapeutics Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 17, 2023
Reporting Period: Month of April 2023
This filing serves as a notification to the U.S. Securities and Exchange Commission regarding the scheduling of the Company's Annual General Meeting of Shareholders.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing.
Guidance, Outlook, and Management Commentary
Corporate Action: The Company has scheduled its Annual General Meeting of Shareholders for May 30, 2023, at 11:00 a.m. Israel time.
Location: 11 Hamenofim St., Building B, Herzliya 4672562, Israel.
Exhibit: A Notice of the Annual General Meeting is included as Exhibit 99.1.
Signatory: Alon Ben-Noon, Chief Executive Officer.
Key Facts for Investor Verification
- Verify the date and time of the Annual General Meeting (May 30, 2023, 11:00 a.m. Israel time).
- Confirm the physical location of the meeting in Herzliya, Israel.
- Review Exhibit 99.1 for the full Notice of the Annual General Meeting to understand agenda items and voting procedures.
- Note that this filing contains no financial results; investors should refer to the most recent Form 20-F or quarterly reports for financial data.